Prutis Nintedanib antifibrotic capsules 100mg and 150mg for IPF, ILDs and SSc-ILD treatment

Softgel Capsules - Supporting Lungs, Slowing Fibrosis

Name: Nintedanib
Brand: Prutis

A clinically proven antifibrotic therapy with Nintedanib, designed to slow lung scarring in interstitial lung disease (ILD), including IPF, PF-ILD, and SSc-ILD.

Available Strengths

100 mg & 150 mg Soft Gelatin Capsules

Learn About ILD Contact Us

About Prutis

Prutis (Nintedanib) is a tyrosine kinase inhibitor with antifibrotic properties.

It works by blocking pathways that drive lung fibrosis, helping preserve lung function and slow disease progression.

Approved Indications

Idiopathic Pulmonary Fibrosis (IPF)
Chronic Fibrosing ILDs with a progressive phenotype
Systemic Sclerosis-Associated ILD (SSc-ILD)

Our Products Range

Prutis 100

Nintedanib Soft Gelatin Capsules - 100 mg

Prutis 150

Nintedanib Soft Gelatin Capsules - 150 mg

Prescribed as per physician guidance based on patient condition.

Benefits & Clinical
Evidence

Slowing decline in lung function (measured by FVC)
Reduces risk of ILD progression events
Clinically proven in global trials (INPULSIS, INBUILD, INJOURNEY)
Long-term safety established (>4 years of follow-up)

Why Early Treatment
Matters

Lung scarring in ILD is irreversible once established.

Early diagnosis through HRCT and PFTs allows timely intervention
Managing progression early can preserve daily activities and improve quality of life

Scientific Information

Frequently Asked Questions

Is Prutis safe during pregnancy or breastfeeding?

How long should I take Prutis?

ILD is a long-term condition. Consistent treatment helps slow progression.

Disclaimer

Prutis (Nintedanib 100 mg/150 mg Soft Gelatin Capsules) is a prescription medicine to be used under the supervision of a registered medical practitioner. Information provided here is for educational purposes only and not a substitute for professional medical advice.